INT17824

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1991
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 6.66
Pain Relevance 10.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Flvcr2) transmembrane transport (Flvcr2)
Anatomy Link Frequency
frontal cortex 9
midbrain 4
smooth muscle 3
hippocampus 3
shell 2
Flvcr2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
gABA 105 100.00 Very High Very High Very High
Dopamine 88 100.00 Very High Very High Very High
Glutamate 82 100.00 Very High Very High Very High
Serotonin 22 100.00 Very High Very High Very High
5HT 5 100.00 Very High Very High Very High
narcan 2 99.90 Very High Very High Very High
Nucleus accumbens 9 99.56 Very High Very High Very High
medulla 7 99.16 Very High Very High Very High
Hippocampus 41 99.04 Very High Very High Very High
midbrain 13 99.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypertension 8 99.48 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 21 99.04 Very High Very High Very High
Pulmonary Hypertension 212 98.92 Very High Very High Very High
Urological Neuroanatomy 14 98.40 Very High Very High Very High
Increased Venous Pressure Under Development 43 95.54 Very High Very High Very High
Nervous System Injury 5 93.60 High High
Schizophrenia 446 91.72 High High
Apoptosis 32 91.12 High High
Injury 25 89.24 High High
Autism 16 88.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Transfection with a single 2.3-kilobase brainstem complementary DNA clone is sufficient to confer expression of a Na(+)-dependent 5HT transporter upon nonneural cells, with transport selectively and potently antagonized by 5HT uptake-specific antidepressants, including paroxetine, citalopram and fluoxetine.
Positive_regulation (confer) of Gene_expression (expression) of transporter in brainstem associated with medulla, antidepressant, 5ht and fluoxetine
1) Confidence 0.41 Published 1991 Journal Nature Section Abstract Doc Link 1944572 Disease Relevance 0.21 Pain Relevance 0.79
Even after denervation of the tail artery (by cutting the postganglionic nerves, Fig. 3(3)) to remove the perivascular terminals (and thus the NE transporter), the responses to phenylephrine were much more enhanced relative to control than those to another ?
Positive_regulation (denervation) of Gene_expression (thus) of transporter in artery
2) Confidence 0.11 Published 2007 Journal Clin Auton Res Section Body Doc Link PMC1797061 Disease Relevance 0 Pain Relevance 0.15
Immunoblot analysis showed that expression of GLT1 (glutamate transporter subtype 1) was identified to be upregulated in synaptosomes but not in total tissues, suggesting a redistribution of glutamate transporter expression.
Neg (not) Positive_regulation (upregulated) of Gene_expression (expression) of transporter associated with glutamate
3) Confidence 0.10 Published 2003 Journal J. Neurosci. Section Abstract Doc Link 12805317 Disease Relevance 0 Pain Relevance 1.17
Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats.
Positive_regulation (transfer) of Gene_expression (transfer) of transporter in shell associated with nucleus accumbens, glutamate, narcan and morphine
4) Confidence 0.06 Published 2005 Journal Eur. J. Neurosci. Section Title Doc Link 16324108 Disease Relevance 0 Pain Relevance 0.77
In primary astrocytic cultures that exhibit an activated phenotype, propentofylline, a glial modulator, induces glutamate transporter GLT-1 expression and glutamate uptake [75].
Positive_regulation (induces) of Gene_expression (expression) of transporter associated with glutamate
5) Confidence 0.06 Published 2009 Journal Mol Pain Section Body Doc Link PMC2806354 Disease Relevance 0.73 Pain Relevance 0.92
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (up) of Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
6) Confidence 0.03 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (-) of Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
7) Confidence 0.02 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (regulation) of Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
8) Confidence 0.02 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
In neonatal rats injected with BPA, a reduction in the midbrain of tyrosine hydroxylase (TH) immunoreactivity occurred with the appearance of TUNEL-positive cells indicating neurodegeneration.108 In that study, BPA also increased gene expression of dopamine (DA) transporter in adult rats after neonatal exposure.
Positive_regulation (increased) of Gene_expression (expression) of transporter in midbrain associated with dopamine and midbrain
9) Confidence 0.02 Published 2009 Journal Schizophrenia Bulletin Section Body Doc Link PMC2643957 Disease Relevance 1.12 Pain Relevance 0.17
In the midbrain of rats injected with BPA at 5 days of age, DA transporter gene expression increases and is associated with hyperactivity.172 These rats were additionally assessed following treatment in the midbrain at 5 days of age with other synthetic endocrine disruptors including dibutylphthalate (DBP), dicyclohexylphthalate (DCHP), and diethylhexylphthalate (DEHP).
Positive_regulation (increases) of Gene_expression (expression) of transporter in midbrain associated with dopamine, midbrain and attention deficit hyperactivity disorder
10) Confidence 0.02 Published 2009 Journal Schizophrenia Bulletin Section Body Doc Link PMC2643957 Disease Relevance 0.51 Pain Relevance 0.44
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Positive_regulation (increased) of Gene_expression (expression) of transporter in smooth muscle associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
11) Confidence 0.02 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 1.02 Pain Relevance 0.13
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (up) of in hippocampus Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
12) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (-) of in hippocampus Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
13) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
Ueda et al (2003) showed that zonisamide could also increase extracellular GABA by the up-regulation of a neuronal glutamate transporter (ie, EAAC-1) and a decreased production of the GABA transporter (ie, GAT-1) in the rat hippocampus and frontal cortex.
Positive_regulation (regulation) of in hippocampus Gene_expression (production) of transporter in frontal cortex associated with glutamate, gaba, urological neuroanatomy and hippocampus
14) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.34 Pain Relevance 0.93
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Positive_regulation (increased) of in fibroblast Gene_expression (expression) of transporter in smooth muscle associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
15) Confidence 0.01 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 1.02 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox